 Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the Class of 2021 IPOs, which featured many companies with preclinical compounds, yet valuations exceeded 1 billion. 